Abnormal MET presence and activity are known to drive tumour growth, persistence and spread. However, although some patients respond well to current therapies many do not, which indicates that there are subtleties about the analysis of MET as a biomarker that have not been adequately analysed to date. CLI chatted with Dr Tony Navas (AbbVie, […]
Background What are circulating tumour cells and extracellular vesicles? Circulating tumour cells (CTCs) are cancer cells that have been shed from a primary tumour into the bloodstream or lymphatic system. They are carried around the body and can be the seeds that form metastases. Extracellular vesicles (EVs) are tiny lipid-bilayer bound particles that are shed […]
According to the most recent statistics provided by Cancer Research UK, lung cancer is the third most common cancer in the UK, with around 49 000 new cases in the UK every year which account for 13% of all new cancer cases.
Breast cancer is the most common cancer in females in the UK, with around 56 800 new cases diagnosed every year.
A new partnership between Surfix Diagnostics, the Netherlands Cancer Institute (NKI), and CRCbioscreen will focus on the validation of novel biomarkers for colorectal cancer (CRC) screening. The collaboration, supported by a PPP grant from the TKI-program Life Sciences & Health of Health~Holland, aims to address the limitations of current screening methods and potentially revolutionise early […]
In a significant advancement for molecular pathology, Indica Labs has launched Lung Macrodissect AI, a novel tool designed to streamline slide macrodissection workflows. The announcement marks a pivotal step in integrating artificial intelligence with digital pathology.
By Dr F. van Delft, Dr M. Schuurbiers, Dr van den Heuvel and Dr H. van Rossum The development of immunotherapy and other targeted therapies has given rise to significant improvements in the treatment of non-small cell lung cancer. However, some patients do not benefit from these therapies and it is, therefore, important for a […]
Although the prevalence of ovarian cancer is fairly low, it is often asymptomatic until after metastasis, resulting in it being the fourth leading cause of cancer death in females in the USA. The development of biomarker screening tests for ovarian cancer has been challenging and the situation is still not satisfactory. Additionally, the tests that […]
by Xijun Min, Dr Yan Li, Liuyan Chen, Chengwei Yao, Dr Xi Qin As a traditional tumour marker for the diagnosis of early primary hepatic carcinoma (PHC), alpha fetoprotein (AFP) has a low positive rate. Serum glypican 3 (GPC3) is a novel biomarker, and the combined examination of GPC3 and AFP will provide a new […]
by Minjie Wang, Binbin Han, Xuexiang Li, Jun Qi Tumour markers play an important role in the detection and management of cancer. It is critical to evaluate new assay systems for precise measurement of commonly used tumour markers in the clinical setting. The goal of this study is to evaluate the performance of […]